Related Experiment Video
Updated: Aug 2, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Unraveling the Post-Translational Modifications and therapeutical approach in NSCLC pathogenesis
Pooja Gulhane1, Shailza Singh1
1National Centre for Cell Science, NCCS Complex, Ganeshkhind, SPPU Campus, Pune 411007, India.
Abstract:
Non-Small Cell Lung Cancer (NSCLC) is the most prevalent kind of lung cancer with around 85% of total lung cancer cases. Despite vast therapies being available, the survival rate is low (5 year survival rate is 15%) making it essential to comprehend the mechanism for NSCLC cell survival and progression. The plethora of evidences suggests that the Post Translational Modification (PTM) such as phosphorylation, methylation, acetylation, glycosylation, ubiquitination and SUMOylation are involved in various types of cancer progression and metastasis including NSCLC. Indeed, an in-depth understanding of PTM associated with NSCLC biology will provide novel therapeutic targets and insight into the current sophisticated therapeutic paradigm. Herein, we reviewed the key PTMs, epigenetic modulation, PTMs crosstalk along with proteogenomics to analyze PTMs in NSCLC and also, highlighted how epi‑miRNA, miRNA and PTM inhibitors are key modulators and serve as promising therapeutics.
Insights
Post-Translational Modifications (PTMs) are crucial in Non-Small Cell Lung Cancer (NSCLC) progression. Understanding these PTMs offers new therapeutic strategies for this prevalent cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Non-Small Cell Lung Cancer (NSCLC) accounts for 85% of lung cancer cases.
- Despite available therapies, NSCLC has a low 5-year survival rate (15%).
- Understanding NSCLC cell survival and progression mechanisms is critical.
Purpose of the Study:
- To review key Post-Translational Modifications (PTMs) involved in NSCLC.
- To explore epigenetic modulation, PTM crosstalk, and proteogenomics in NSCLC.
- To identify novel therapeutic targets and strategies for NSCLC.
Main Methods:
- Literature review of PTMs in NSCLC.
- Analysis of epigenetic modulation and PTM crosstalk.
- Examination of proteogenomic data related to PTMs.
Main Results:
- PTMs like phosphorylation, methylation, acetylation, glycosylation, ubiquitination, and SUMOylation are implicated in NSCLC progression and metastasis.
- Epigenetic modifications and PTM crosstalk play significant roles in NSCLC biology.
- Proteogenomics provides insights into PTMs within the NSCLC context.
Conclusions:
- In-depth understanding of PTMs in NSCLC is essential for developing novel therapeutic targets.
- Epi-miRNA, miRNA, and PTM inhibitors show promise as therapeutic modulators for NSCLC.
- Targeting PTMs offers a sophisticated approach to NSCLC treatment paradigms.
More Related Videos
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
08:12Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins
Published on: January 8, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:04Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
02:23Abnormal Proliferation
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...